Telemonitoring of Outpatients With Heart Failure A Search for the Holy Grail?

Department of Cardiology, University Medical Center Groningen, University of Groningen, PO Box 30.001, 9700RB Groningen, The Netherlands. .
Circulation (Impact Factor: 14.43). 05/2012; 125(24):2965-7. DOI: 10.1161/CIRCULATIONAHA.112.118141
Source: PubMed


Heart failure (HF) remains a large medical problem, and prevention of decompensation and HF-related hospitalizations is important, not only for the patient, but also from an economic point of view. Close monitoring is crucial, and can be done through a whole spectrum of modalities. This ranges from a (nurse-based) disease management program, to structured telephone support, to remote or telemonitoring with or without the use of an implantable device(1-3). (SELECT FULL TEXT TO CONTINUE).

Full-text preview

Available from:
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Heart failure patients with implantable defibrillators place a significant burden on health care systems. Remote monitoring allows assessment of device function and heart failure parameters, and may represent a safe, effective, and cost-saving method compared to conventional in-office follow-up. We hypothesized that remote device monitoring represents a cost-effective approach. This paper summarizes the economic evaluation of the Evolution of Management Strategies of Heart Failure Patients With Implantable Defibrillators (EVOLVO) study, a multicenter clinical trial aimed at measuring the benefits of remote monitoring for heart failure patients with implantable defibrillators. Two hundred patients implanted with a wireless transmission-enabled implantable defibrillator were randomized to receive either remote monitoring or the conventional method of in-person evaluations. Patients were followed for 16 months with a protocol of scheduled in-office and remote follow-ups. The economic evaluation of the intervention was conducted from the perspectives of the health care system and the patient. A cost-utility analysis was performed to measure whether the intervention was cost-effective in terms of cost per quality-adjusted life year (QALY) gained. Overall, remote monitoring did not show significant annual cost savings for the health care system (€1962.78 versus €2130.01; P=.80). There was a significant reduction of the annual cost for the patients in the remote arm in comparison to the standard arm (€291.36 versus €381.34; P=.01). Cost-utility analysis was performed for 180 patients for whom QALYs were available. The patients in the remote arm gained 0.065 QALYs more than those in the standard arm over 16 months, with a cost savings of €888.10 per patient. Results from the cost-utility analysis of the EVOLVO study show that remote monitoring is a cost-effective and dominant solution. Remote management of heart failure patients with implantable defibrillators appears to be cost-effective compared to the conventional method of in-person evaluations. NCT00873899; (Archived by WebCite at
    Full-text · Article · May 2013 · Journal of Medical Internet Research
  • [Show abstract] [Hide abstract]
    ABSTRACT: Heart failure with normal left ventricular (LV) ejection fraction (HF-NEF), sometimes named diastolic heart failure, is a common condition, most frequent in the elderly and is associated with arterial hypertension and LV hypertrophy. Prognosis is almost as severe as for heart failure with reduced EF, in part reflecting comorbidities. Because the heart failure diagnosis is based on relatively nonspecific symptoms and signs, it is important to apply objective measures of diastolic function when evaluating patients with potential HF-NEF. In the absence of invasive data, this is done by echocardiography to demonstrate signs of impaired relaxation, increased diastolic stiffness, or elevated LV filling pressure. The echocardiographic measures include transmitral, pulmonary venous, and intraventricular flow velocities and estimation of systolic pulmonary artery pressure from tricuspid regurgitation velocity. In addition, LV lengthening velocity by tissue Doppler should be measured. It is important to search for consistency between measures since no single variable provides sufficient diagnostic information. Treatment of HF-NEF is symptomatic, with similar drugs as in heart failure with reduced EF.
    No preview · Chapter · Jan 2013
  • [Show abstract] [Hide abstract]
    ABSTRACT: Extravascular lung water is a crucial parameter for the management of many different pathological conditions, especially heart failure. Many modalities can be employed for its evaluation, each with different advantages and limitations. In a near future, we hope that extravascular lung water assessment could be performed by non-invasive wearable devices, allowing remote continuous monitoring of pulmonary congestion. Recently, it has been proposed that some specific genetic variations may be responsible for the heterogeneous individual response to the development of extravascular lung water. These data could be relevant to titrate and personalize both treatments and preventive interventions.
    No preview · Article · Apr 2013 · Recenti progressi in medicina
Show more